Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

<p>NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer’s Disease Research Unit and the Yale Alzheimer’s Disease Research Center, is presenting the Phase 2 study design of the company’s ongoing START study in an oral late-breaking session at Clinical […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/cognition-therapeutics-and-collaborators-at-yale-and-actc-announce-oral-late-breaking-presentation-on-the-start-study-in-early-alzheimers-disease-at-ctad/">Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>